Heart Failure Clinical Trial
— VACHFOfficial title:
Significance of Regional Ventriculo-arterial Coupling in Patients With Chronic Heart Failure: Effects of Endothelial Progenitor Cells and a Direct Renin Inhibitor
Verified date | June 2010 |
Source | Taipei Veterans General Hospital, Taiwan |
Contact | n/a |
Is FDA regulated | No |
Health authority | Taiwan: Institutional Review Board |
Study type | Interventional |
Heart failure is a major health problem worldwide. Optimal treatment of this disabling and
fatal condition may require functional characterization of the failed left ventricle (LV)
and its interaction with the arterial system. Part of the physiological significance of the
ventriculo-arterial coupling has been studied experimentally and clinically using the
framework of the ratio of effective arterial elastance (Ea) to end-systolic elastance (Ees),
with limited clinical applications.
From central ascending aorta to terminal arterioles, every segment of the arterial tree
contributes to the arterial loads that interact and impact LV performance in both systole
and diastole, leads to atrial and ventricular remodeling and hypertrophy, and results in the
development of heart failure. On the other hand, the ventricular systole is a complex
coordination of multi-directional myocardial fibers involving longitudinal contraction,
circumferential shortening, radial thickening, twist, and torsion, the so-called LV
deformations.
The purposes of the present study are to investigate the relationship between different
components of hemodynamic load or arterial abnormalities and different components of LV
myocardial deformations or regional LV function, the modulating effects of endothelial
progenitor cells (EPCs) on the ventriculo-arterial coupling, and the therapeutic effects of
aliskiren on the components of hemodynamic load and LV myocardial deformations and their
couplings. The investigators will also investigate whether the ventriculo-arterial coupling,
EPCs, and add-on therapy of aliskiren predict cardiovascular outcomes.
Status | Not yet recruiting |
Enrollment | 120 |
Est. completion date | |
Est. primary completion date | July 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: 1. Outpatients = 18 years of age, male or female. Female patients must be either post-menopausal for one year, surgically sterile, or using effective contraceptive methods such as oral contraceptives, barrier method with spermicide or an intrauterine device. 2. Patients with a diagnosis of chronic heart failure (NYHA Class II-IV) and reduced systolic function: LVEF = 45% at Visit 1 (local measurement, measured within the past 6 months assessed by echocardiogram, MUGA, CT scan, MRI or ventricular angiography). 3. NT-pro BNP = 600pg/ml (BNP = 150 pg/ml) at Visit 1 or NT-pro BNP = 450 pg/mL (BNP (= 100 pg/ml) and a hospitalization for HF within last 12 months 4. Patients must be on a stable dose of either an ACE inhibitor or an ARB for at least 4 weeks prior to Visit 1. 5. Patients must be treated with a beta blocker, unless contraindicated or not tolerated, at a stable dose for at least 4 weeks prior to Visit 1. 6. Patients with documented sinus rhythm at Visit 1. - Exclusion Criteria: 1. History of hypersensitivity to any of the study drugs. 2. Patients who require treatment with both ACEI and ARB. 3. Current acute decompensated HF (exacerbation of chronic HF manifested by signs & symptoms that may require IV therapy). 4. Symptomatic hypotension and/or less than 100 mmHg at the time of screening or less than 90 mmHg at the time of randomization. 5. eGFR < 30 ml/min/1.73m2 as measured by the MDRD formula at Visit 1 (screening) , or a > 25% decrease after 14 days of active run-in period. 6. Serum potassium > 5.0 mmol/L at screening (Visit 1). 7. Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or major vascular surgery, percutaneous coronary intervention (PCI) or carotid angioplasty, within the past 3 months prior to visit 1. 8. Coronary or carotid artery disease likely to require surgical or percutaneous intervention within the 6 months after Visit 1. 9. Patients with active or unstable bronchospasm or asthma (patients must be on stable regimen of respiratory medications for 1 month prior to Visit 1). 10. Right heart failure due to severe pulmonary disease. 11. Diagnosis of peripartum or chemotherapy induced cardiomyopathy within the 12 months prior to visit 1. 12. Patients with a history of heart transplant or who are on a transplant list or with left ventricular assistance device (LVAD device). 13. Documented ventricular arrhythmia with syncopal episodes within past 3 months, prior to visit 1, that is untreated. 14. Symptomatic bradycardia or second or third degree heart block without a pacemaker. 15. Implantation of a CRT (cardiac resynchronization therapy) device within the prior 3 months from visit 1 or intent to implant a CRT device. 16. Presence of hemodynamically significant mitral and/or aortic valve disease, except mitral regurgitation secondary to left ventricular dilatation. 17. Presence of other hemodynamically significant obstructive lesions of left ventricular outflow tract, including aortic and sub-aortic stenosis. 18. Severe primary pulmonary, renal or hepatic disease. 19. Presence of any other disease with a life expectancy of < 1 year. 20. Chronic long-term requirement for NSAIDs (high dose) or COX2 inhibitors, with the exception of aspirin at doses used for CV prophylaxis (=325 mg o.d.). 21. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs 22. Subjects get pregnant or will be pregnant within 6 months. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Taiwan | National Taiwan University Hospital | Taipei | |
Taiwan | Taipei Veterans General Hospital | Taipei |
Lead Sponsor | Collaborator |
---|---|
Taipei Veterans General Hospital, Taiwan | National Science Council, Taiwan |
Taiwan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | LV systolic function, the global longitudinal strain | During 1-year treatment, ventricular systolic functions would be measured by using speckle tracking and presented as global longitudinal, circumferential, and radial strain at baseline and at the end of study. The changes of strain would be compared between 2 study groups. | 1 year | No |
Secondary | plasma NT-proBNP level | After 1 year, plasma NT-proBNP will be re-checked. The differences between on-treatment and baseline NT-proBNP levels will be compared between 2 groups. | 1 year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Active, not recruiting |
NCT05896904 -
Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction
|
N/A | |
Completed |
NCT05077293 -
Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
|
||
Recruiting |
NCT05631275 -
The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
|
||
Enrolling by invitation |
NCT05564572 -
Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology
|
N/A | |
Enrolling by invitation |
NCT05009706 -
Self-care in Older Frail Persons With Heart Failure Intervention
|
N/A | |
Recruiting |
NCT04177199 -
What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
|
||
Terminated |
NCT03615469 -
Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY)
|
N/A | |
Recruiting |
NCT06340048 -
Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure
|
Phase 1/Phase 2 | |
Recruiting |
NCT05679713 -
Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
|
||
Completed |
NCT04254328 -
The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure
|
N/A | |
Completed |
NCT03549169 -
Decision Making for the Management the Symptoms in Adults of Heart Failure
|
N/A | |
Recruiting |
NCT05572814 -
Transform: Teaching, Technology, and Teams
|
N/A | |
Enrolling by invitation |
NCT05538611 -
Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
|
||
Recruiting |
NCT04262830 -
Cancer Therapy Effects on the Heart
|
||
Completed |
NCT06026683 -
Conduction System Stimulation to Avoid Left Ventricle Dysfunction
|
N/A | |
Withdrawn |
NCT03091998 -
Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support
|
Phase 1 | |
Recruiting |
NCT05564689 -
Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy
|